Member Info for BuenaVista

Fusion had a MCap of $1,013m (~£797.9m) the day before the acquisition announcement, so just under 5x the size of Avacta.

It's not two years worth of financing. It's one years worth until more financing needs to be found.

Which came first: poor comms or poor strategy?

@Bella, if he's been there almost 10 years then he's another one that needs to go as well as, not instead of.

Comms, strategy, financing - all trash.

And the RNS announcing AS and TG standing down and search starting for new CEO and CFO.

AS has a lot of explaining to do. Will he be forthcoming and honest though? That's the question.

Imo, we do need a new CEO and CFO, ones with pharma industry experience and track records of success. However, neither will be voted out by shareholders. The 50p placing to IIs has seen to that. IIs would vote to keep them and IIs will be who AS will now be working to please. It doesn't change the fact that AS's and TG's credibility are shot and irredeemable as far as PIs are concerned.

No one should give any weight to what AS says.

The clinicians however present a consistently positive story.

I don't think anything about TheValueCurve. She just throws out unqualified, simplistic statements. No one should fall for such rubbish: if someone makes a contrary statement without any reasoning or argument, that statement should be ignored. Anyone can make anything up. Doesn't mean it should be entertained, even if TheValueCurve did go with five men last night.🥴

I can 💯 guarantee TheValueCurve hasn't read the AZ/Fusion news and wouldn't understand it even if she had.

TheValueCurve spouts lying FUD as usual.

It's a different type of platform and a specific type of cancer (akin to what Point Biopharma were doing and targeting) and Fusion have a candidate in Phase 2.

$2bn, or $2.4bn on milestones. Fusion have a radioconjugate for prostate cancer in Phase 2

https://www.londonstockexchange.com/news-article/AZN/astrazeneca-to-acquire-fusion/16383367

AVA6000 is a prodrug. pre|CISION is the platform.

If he's a FAP man he'll know all about the pre|CISION platform ...or he's not worth his salt.

FAP is associated with tissue remodelling - tissue/cancer growth. Not surprising that high (active) FAP = fast growing tumour = rapid death.

@Bella, surely "a very clear update" is simply one where there is no ambiguity, no obvious omissions and nothing that can be dissected and the bones picked over on here.

Absolutely correct notrex - Avacta can't get AVA6000 to market by themselves. AS has said as much. A deal with a big company with deep pockets is what will give the platform the credibility that mushy words from AS don't.

"The precautionary principle is a broad epistemological, philosophical and legal approach to innovations with potential for causing harm when extensive scientific knowledge on the matter is lacking. It emphasizes caution, pausing and review before leaping into new innovations that may prove disastrous."

- - - - -

"The precautionary principle enables decision-makers to adopt precautionary measures when scientific evidence about an environmental or human health hazard is uncertain and the stakes are high. It first emerged during the 1970s and has since been enshrined in a number of international treaties on the environment, in the Treaty on the Functioning of the European Union and the national legislation of certain Member States. The precautionary principle divides opinions. To some, it is unscientific and an obstacle to progress. To others, it is an approach that protects human health and the environment. Different stakeholders, experts and jurisdictions apply different definitions of the principle, mainly depending on the degree of scientific uncertainty required for the authorities to take action. Although most experts agree that the precautionary principle does not call for specific measures (such as a ban or reversal of the burden of proof), opinions are divided on the method for determining when to apply precautionary measures. The application of the precautionary principle presents many opportunities as well as challenges. The precautionary principle is closely linked to governance. This has three aspects: risk governance (risk assessment, management and communication), science-policy interfaces and the link between precaution and innovation."

This is why it takes so long to get a drug on the market and why those proposing shortcuts that contravene this principle are talking b o l l o c k s.

@Bella's "Once the company gets out from under any comms restrictions they may be under, I'm sure we will get a very clear update."

😂😂😂 Do you want to bet on that?

They have to start getting partners onboard, whether that is through license deals or a big company taking a stake and a seat on the board doesn't matter to me but they need, within the coming months, to do what they have been spectacularly incapable of doing so far, which is clinching a good deal and securing revenue beyond 2025.

Aptamer have ties to Leeds Uni don't they?

"Great scientist - no doubt about that" - What evidence do you base that opinion on notrex? I would say that he's good at spotting opportunities. He's sharp. He's an opportunist. I've seen no evidence of his scientific prowess.

On licensing deals, are we not expecting deals over the next year? No deals means no revenue, means another fundraise and further dilution. Surely a deal to get the logjam loosened would be welcome, even if the terms aren't massively big or favourable, financial details don't have to be disclosed, just something to show the investment community that pharma are taking the pre|CISION platform seriously and for the rest of pharma to realise that deals have started. Something along the lines of a big pharma company licensing the platform for prodrugs for undisclosed indications.